International journal of dermatology, vol.55, no.12, pp.1362-1368, 2016 (SCI-Expanded)
BackgroundPemphigus vulgaris (PV) is a severe, chronic, and potentially life-threatening autoimmune blistering disease that affects the skin and mucous membranes. Rituximab is a monoclonal anti-CD20 antibody which has been used increasingly in the therapy of PV.